Poltreg (PTG) Stock Overview
A biotechnology company, researches and develops therapies for autoimmune diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
PTG Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Poltreg S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł26.60 |
| 52 Week High | zł44.20 |
| 52 Week Low | zł22.70 |
| Beta | 0.76 |
| 1 Month Change | 5.14% |
| 3 Month Change | -1.85% |
| 1 Year Change | -39.82% |
| 3 Year Change | -42.17% |
| 5 Year Change | n/a |
| Change since IPO | -57.09% |
Recent News & Updates
Recent updates
We're Hopeful That Poltreg (WSE:PTG) Will Use Its Cash Wisely
Sep 02
Poltreg (WSE:PTG) Is In A Good Position To Deliver On Growth Plans
May 08We Think Poltreg (WSE:PTG) Needs To Drive Business Growth Carefully
Dec 24Will Poltreg (WSE:PTG) Spend Its Cash Wisely?
Sep 10Is Poltreg (WSE:PTG) In A Good Position To Invest In Growth?
Mar 13Here's Why We're Not Too Worried About Poltreg's (WSE:PTG) Cash Burn Situation
Jun 21We Think Poltreg (WSE:PTG) Can Afford To Drive Business Growth
Oct 05Here's Why We're Not Too Worried About Poltreg's (WSE:PTG) Cash Burn Situation
Jun 16Poltreg (WSE:PTG) Is In A Good Position To Deliver On Growth Plans
Feb 24Shareholder Returns
| PTG | PL Biotechs | PL Market | |
|---|---|---|---|
| 7D | 8.6% | -4.0% | 3.0% |
| 1Y | -39.8% | -5.0% | 31.4% |
Return vs Industry: PTG underperformed the Polish Biotechs industry which returned -5% over the past year.
Return vs Market: PTG underperformed the Polish Market which returned 31.4% over the past year.
Price Volatility
| PTG volatility | |
|---|---|
| PTG Average Weekly Movement | 6.2% |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in PL Market | 8.7% |
| 10% least volatile stocks in PL Market | 2.9% |
Stable Share Price: PTG has not had significant price volatility in the past 3 months compared to the Polish market.
Volatility Over Time: PTG's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 33 | Piotr Trzonkowsk | poltreg.tech |
Poltreg S.A., a biotechnology company, researches and develops therapies for autoimmune diseases. It engages in the development of therapies for the treatment of type 1 diabetes in children, as well as multiple sclerosis. The company was incorporated in 2016 and is based in Gdansk, Poland.
Poltreg S.A. Fundamentals Summary
| PTG fundamental statistics | |
|---|---|
| Market cap | zł117.52m |
| Earnings (TTM) | -zł24.56m |
| Revenue (TTM) | n/a |
Is PTG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PTG income statement (TTM) | |
|---|---|
| Revenue | zł0 |
| Cost of Revenue | zł5.49m |
| Gross Profit | -zł5.49m |
| Other Expenses | zł19.07m |
| Earnings | -zł24.56m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.27 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PTG perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/15 20:07 |
| End of Day Share Price | 2025/12/15 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Poltreg S.A. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kamil Kliszcz | Biuro maklerskie mBanku |
| Beata Szparaga-Wasniewska | Biuro maklerskie mBanku |
| Lukasz Kosiarski | Ipopema Securities S.A. |